Recent Annual Reports

Browse the latest SEC filings with AI-powered analysis. Get insights into corporate performance, financial trends, and business developments.

📊 4604 Reports

🤖 AI Analyzed

Recent

📄 Page 8 of 384

Virgin Galactic Holdings, Inc

10-K March 30, 2026

Key Highlights

Successful completion of six commercial flights in six months during 2024.
Development of the Delta Class fleet, designed to carry six passengers per fligh...
Scalable business model targeting up to 125 flights per year with new ships.

Read Analysis

🤖 AI Generated

Inmune Bio, Inc.

10-K March 30, 2026

Key Highlights

Lead drug CORDStrom showed safety and efficacy in Phase 2 trials for RDEB.
Targeting regulatory filings for CORDStrom in the UK, EU, and U.S. by late 2026.
FDA granted CORDStrom 'Orphan Drug' status, providing tax credits and 7-year mar...

Read Analysis

🤖 AI Generated

Ensysce Biosciences, Inc.

10-K March 30, 2026

Key Highlights

Proprietary TAAP and MPAR platforms designed to create safer, abuse-deterrent pa...
Advancing lead clinical-stage candidates PF614 and PF614-MPAR through Phase 3 tr...
Focused on addressing the critical market need for non-opioid or safer pain mana...

Read Analysis

🤖 AI Generated

PSNH FUNDING LLC 3

10-K March 30, 2026

Key Highlights

Predictable, state-regulated cash flows from mandatory customer fees
Bankruptcy-remote structure protects assets from parent company risks
Consistent debt repayment schedule with full principal and interest paid in 2025

Read Analysis

🤖 AI Generated

MeiraGTx Holdings plc

10-K March 30, 2026

Key Highlights

Vertically integrated manufacturing capabilities with commercial-grade authoriza...
Proprietary 'riboswitch' technology acts as a biological dimmer switch for preci...
Strategic partnership with Johnson & Johnson provides non-dilutive capital and m...

Read Analysis

🤖 AI Generated

REVIVA PHARMACEUTICALS HOLDINGS, INC.

10-K March 30, 2026

Key Highlights

Advancing Brilaroxazine as a potential treatment for schizophrenia
Successfully raised $15 million in capital to sustain clinical operations
Focused on reaching critical RECOVER-2 trial results in 2026

Read Analysis

🤖 AI Generated

Fathom Holdings Inc.

10-K March 30, 2026

Key Highlights

Cloud-based brokerage model offers agents 25% higher earnings than traditional f...
New 2024 revenue streams include Fathom Max flat-fee and Fathom Share recruitmen...
Strategic focus on increasing 'attach rates' for mortgage, title, and insurance ...

Read Analysis

🤖 AI Generated

Lantern Pharma Inc.

10-K March 30, 2026

Key Highlights

FDA clearance for two Phase 1b/2 clinical trials for lead drug LP-184.
Launch of withZeta.ai, a generative AI co-scientist that accelerates biomarker d...
Expansion of RADR® platform with 160+ new machine learning algorithms, including...

Read Analysis

🤖 AI Generated

Unicycive Therapeutics, Inc.

10-K March 30, 2026

Key Highlights

Lead drug OLC has a critical FDA target decision date of June 29, 2026.
Resubmission of OLC application follows successful resolution of manufacturing q...
Development of UNI-494 offers potential for treating Acute Kidney Injury, a mark...

Read Analysis

🤖 AI Generated

American Picture House Corp

10-K March 30, 2026

Key Highlights

Strategic shift from consulting to film financing and production
Priority repayment rights on film loans ensure first-position claims
Growing library of five completed films generating recurring revenue

Read Analysis

🤖 AI Generated

AEP Texas Restoration Funding LLC

10-K March 30, 2026

Key Highlights

Stable, predictable cash flows backed by mandated utility charges.
Special-purpose structure designed specifically for bond repayment.
Regulatory 'true-up' mechanism ensures revenue aligns with debt obligations.

Read Analysis

🤖 AI Generated

CISO Global, Inc.

10-K March 30, 2026

Key Highlights

Strong recurring revenue model with 70% to 80% of income coming from monthly sub...
Significant cross-selling potential with only 20% of the 437-client base current...
Strategic shift to a product-led model using internal automation to improve prof...

Read Analysis

🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from annual reports with our AI-powered analysis. Track corporate performance, financial trends, and strategic developments.

Back to Homepage